These data suggest that the induction of mutations in specific tumor suppressor genes or oncogenes in oral tumors may be associated with specific carcinogen exposures, and that this association may be linked to specific polymorphic genotypes in xenobiotic-metabolizing enzyme genes.
Introduction
The induction of aerodigestive tract neoplasia is highly associated with exposure to tobacco procarcinogens. Cytochrome P4501A1 (CYP1A1*) and glutathione S-transferase M1 (GSTM1) are xenobiotic metabolizing enzymes (XMEs) that are involved in the metabolism of strong tobacco carcinogens such as polycyclic aromatic hydrocarbons (PAHs) like benzo[a]pyrene (BaP; 1,2). It has been suggested that the null [(0/0)] GSTM1 genotype results in increased risk for tobaccorelated cancers due to a decreased ability to detoxify PAHs (3) (4) (5) (6) and has been demonstrated to be associated with increased risk for several tobacco-related cancers including lung cancer (5) . Similarly, the AϾG polymorphism at codon 462 in exon 7 of the CYP1A1 gene, resulting in an ile:val amino acid change in the CYP1A1 enzyme, has been shown to result in increased activity of the CYP1A1 val isozyme towards various substrates including 7-ethoxy-resorufin (7) (8) (9) and both (R)6-and (R)8-hydroxy-warfarin (9) . This polymorphism has also been associated with increased risk for lung cancer (10, 11) . Therefore, the polymorphic expression of these XMEs, leading to inter-individual differences in metabolic capacities, may be involved in individual differences in risk for tobacco-related cancer induction.
Squamous cell carcinoma is the most common malignant neoplasm of the oral mucosa, representing~90% of oral malignant tumors (12) . A high prevalence of mutations in both the p53 (13, 14) and p16 (15) (16) (17) (18) (19) (20) tumor suppressor genes have been reported in head and neck carcinomas. In oral cavity squamous cell carcinomas (OCSCCs), the incidence of single base pair/small deletion mutations has been shown to be as high as 63% for the p53 gene (21) , whereas up to 20% of such mutations have been reported in the p16 gene (19, 20) . We and others have previously reported on the association between OCSCC p53 mutation prevalence and spectra with levels of tobacco use in oral cancer patients (13, 22) . The link between specific p53 mutation induction and exposure to specific tobacco smoke carcinogens has been further reinforced by recent studies demonstrating that benzo[a]pyrene 7S,8R-diol 9S,10R-oxide (BPDE) induces specific p53 mutations at 'hot-spot' locations in vitro similar to those observed in human lung tumors in vivo (23) . These studies suggest that mutational alterations in target genes may accumulate via highly specific events and carcinogenic pathways. Furthermore, previous studies have demonstrated an association between p53 mutation prevalence and the prevalence of the CYP1A1 val allele, but not GSTM1 (0/0) genotype, in Japanese patients with lung tumors (24) . These studies are highly suggestive of a link between tobacco carcinogen metabolism in vivo, tumor-inducing mutations and increased risk for tobacco-related cancers.
The overall goal of our studies has been to elucidate mechanisms of genetic predisposition to oral cancer. We have previously demonstrated a non-tobacco-related association between the CYP1A1 (ile:val) polymorphism and oral cancer susceptibility (25) . To determine if this association extends to target gene mutations in oral tumors, we extended a previous analysis of 48 OCSCCs for p53 mutations (13) , and correlated p53 mutation prevalence and spectra with the polymorphic prevalences for CYP1A1 (ile:val) and GSTM1 null polymorphisms. To determine if specific XME polymorphisms are potentially associated with mutations in specific target genes, we also performed this analysis for single base pair/small deletion mutations induced in another tumor suppressor gene, p16. In addition, we extended this study to examine the relationship between mutations and genotype in conjunction with exposure to known environmental risk factors for oral cancer (i.e. tobacco use and alcohol consumption).
Materials and methods

Patients and tumor tissues
Eighty patients with squamous cell carcinoma of the oral cavity who were undergoing surgical resection at either Memorial Sloan-Kettering Cancer Center or the New York Eye and Ear Infirmary were prospectively entered into this study after approval by the appropriate institutional review boards. Clinical data pertaining to tumor site were collected from patient charts for all oral cancer subjects recruited into the study. All tumors were obtained solely from anatomical sites within the oral cavity other than the lip, gum or hard palate, and not from other organ sites such as the larynx. All tumor samples contained Ͻ30% normal tissues as determined by pathological analysis.
Clinical data
The laboratory was kept blinded to the clinical history of all subjects. Demographic information, as well as information on tobacco use and alcohol consumption for all cases was collected by administering a short questionnaire by subject interview. Smoking levels were calculated as the sum of cigarettes, pipes and cigars smoked according to the equivalents adopted previously, i.e. 20 cigarettes ϭ 4 cigars ϭ 5 pipes ϭ 1 pack (26), with our data calculated as pack-years (1 pack/day for 1 year ϭ 1 pack-year). Never-smokers were defined as subjects who smoked Ͻ1 pack-year. One patient was a life-long non-smoking tobacco chewer. Alcohol exposure was classified as: neverdrinker (ND) ϭ Ͻ0.1 shots/day; light drinker (LD) ϭ 0.1-1 shots/day; moderate drinker (MD) ϭ 1.1-4.0 shots/day; and heavy drinker (HD) ϭ Ͼ4.0 shots/day. Of the 80 patients, there were four ex-heavy drinkers (quit ജ5 years ago) who were included in the heavy drinker category for our analysis. One shot ϭ 12.9 g of 43% alcohol, which is roughly equivalent to 1 oz of 86-proof hard liquor, one 3.6 oz glass of wine or one 12 oz can of beer. For many of the subjects that were interviewed, we could not obtain accurate lifetime alcohol use data, but were able to collect determinations on the peak amount of alcohol consumption. All cases who were drinkers drank for a minimum of ten years. Clinical data were also obtained on patient age and sex. The average age of this patient series was 63.3 Ϯ 12.3 years.
Isolation and purification of DNA Tumors tissue was obtained during surgery and excised independently. Tissues were immediately frozen at -70°C after surgical resection. Slices (100-500 mg) of partially-thawed tumor tissue were snap-frozen in liquid nitrogen and pulverized prior to homogenization in proteinase K (0.1 mg/ml)-containing buffer [10 mM Tris-HCl (pH 8.0)/1 mM EDTA (TE)] and treated with RNase A (1 µg/ml) at 37°C for 30 min, prior to quantitation by spectrophotometry (13) . Final DNA pellets were resuspended in TE buffer.
To prevent cross-contamination during polymerase chain reaction (PCR), all amplifications were performed using fresh, sterile autoclaved tips, tubes and double distilled water. Careful attention was given throughout to prevent cross-contamination between samples during DNA purification and isolation. All equipment utilized for tissue blending and homogenization were washed in a bath of concentrated chromic:sulfuric acid, rinsed three times in autoclaved double distilled water and once in 70% ethanol, air-dried and autoclaved.
PCR amplifications
All PCR amplifications were performed in a GenAmp 9600 thermocycler (Perkin Elmer) using Taq DNA polymerase (Boehringer Mannheim). The standard PCR was composed of a 100 µl reaction volume containing 100 ng of purified genomic DNA. p53 exons 5-9 were amplified as previously described (13, 27) . These regions of p53 are known to contain Ͼ95% of the p53 mutations in human cancers (28) . p16 exon 1 was amplified using the following primers: sense (-67 nt to -45 nt, relative to p16 exon 1 translation start site), 5Ј-CTGCGGAGAGGGGGAGAGCAGGC-3Ј; and antisense (ϩ67 nt to ϩ86 nt, relative to p16 exon 1 3Ј splice site), 5Ј-GCGCTACCTGATTCC-AATTC-3Ј. p16 exon 2 was amplified using the following primers: sense 510 (-26 to -7 nt relative to the 5Ј-end of p16 exon 2), 5Ј-TCTGACCATTCTGTT-CTCTC-3Ј; and antisense (ϩ32 to ϩ53 nt relative to the 3Ј-end of p16 exon 2), 5Ј-CTCTGAGCTTTGGAAGCTCTCA-3Ј. Amplifications of both p16 exons were performed as described above for p53 exon 8 (13, 27) in the presence of 5% formamide with an annealing temperature of 58°C for 20 s. CYP1A1 exon 7 was PCR-amplified as previously described (10, 25) . PCR products were electrophoresed on 8% polyacrylamide gels and visualized on UV light after ethidium bromide staining.
Single strand conformational polymorphism (SSCP) and sequencing analysis
The SSCP technique was used to screen all tumor DNA samples for structural aberrations in the p53 and p16 genes. Analysis for LOH was not performed for either of these genes in this series of tumors due to an insufficient quantity of DNA in many of the samples. This technique was also utilized for CYP1A1 (ile:val) codon 462 polymorphism genotyping as previously described (25) . For SSCP, PCR amplifications were performed in the presence of 0.5 µl of [α-32 P]dATP (800 Ci/mmol, 10 mCi/ml; Dupont). Purified PCR products (5000 cpm) were subjected to electrophoresis on 0.4 mm thick 8% polyacrylamide gels containing 10% glycerol for 16 h at 4°C. Gels were dried and autoradiographed after electrophoresis and all autoradiographs were analysed by at least three independent individuals involved in this study to determine possible shifts in the banding patterns of p53, p16 and CYP1A1 exons. Confirmation of SSCP analysis was performed by repeating SSCP for all p53-and p16-shifted samples, and CYP1A1 genotyping results were confirmed in 10% of all samples. For p53 and p16, shifted bands were excised, eluted, re-PCR amplified and used for dideoxy sequencing as previously described (13, 27) . Sequencing was performed with both sense and anti-sense primers and was repeated for two independent SSCP-shifted bands to rule out nonspecific misincorporations induced by Taq DNA polymerase.
GSTM1 assay
The presence of the GSTM1 null polymorphism [homozygous (0/0)] was screened using a 3Ј-primer-based PCR assay as previously described (25, 29) . This assay enabled us to screen both the GSTM1 and GSTM4 genes simultaneously in one PCR reaction. The GSTM4 gene is a non-polymorphic µ-class gene exhibiting high homology (Ͼ90%) with GSTM1 in the 5Ј-sense primer site, but little homology in the 3Ј anti-sense primer site. In this PCR assay, tumor DNA was used to screen for exon 4-5 sequences in both genes, with GSTM4 exon 4-5 amplifications serving as a positive control for each reaction.
Statistics
Odds ratio (OR) estimates of the relative risk with 95% confidence intervals (CIs) were used for our statistical analysis. All P values were calculated based upon χ 2 and/or Fisher's exact test. The Student's t-test was utilized for all comparative analysis of smoking (i.e. pack-year) data.
Results
In previous studies, we demonstrated that the prevalence of p53 mutations in OCSCCs was correlated with levels of patient tobacco use but not alcohol consumption (13) . We also showed that G:C Ͼ A:T transitions and G:C Ͼ T:A transversions were the most common types of base pair substitutions induced at the p53 locus in these tumors, a pattern consistent with the types of mutations induced by tobacco carcinogens such as tobacco-specific nitrosamines (TSNAs) like 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (14, 30, 31) , or PAHs like BaP (23, 32) . To determine whether differences in XME genotype play a role in OCSCC target gene mutation induction, we extended previous studies of p53 mutation prevalence and spectrum in OCSCCs by examining an additional 37 OCSCCs for p53 exon 5-9 mutations, and the entire series of 80 OCSCCs for p16 exon 1-2 base pair mutations and small deletions. As shown in Table I ,~40% of the OCSCCs were mutated in the p53 gene. No p53 mutational 'hot-spots' were observed, with 66% of these mutations mis-sense (resulting in amino acid changes), 9% were nonsense mutations (encoding translational stop codons), 19% were small deletions resulting in frameshifts and 6% splice site mutations resulting from intronic base pair substitutions (Table I) .
For our mutational analysis of the p16 gene in this series of oral tumors, we focused on the elucidation of small base (Table I) . Five additional tumors exhibited base pair alterations (G:C Ͼ A:T) at codon 140, resulting in an amino acid change of alanine to threonine. However, this alteration has been previously described as a germ-line polymorphism (15, 18) and was excluded from our mutational analysis (corresponding normal tissue from individual patients was not available to examine this directly). The polymorphic frequency observed for this p16 codon 140 alteration in the present study (5/69, 7%) was nearly identical to that observed in previous studies (15) . Potential mutational hot-spots were observed for p16 codons 61 (three mutations) and 102 (two mutations), both of which have not been previously identified as germ-line polymorphisms. In total, 17% of the p16 mutations were missense, 58% were nonsense, 17% were deletions and 8% were intronic base pair substitutions resulting in splice site mutations (Table I) . Of the 74 OCSCCs from which informative results were obtained for both p53 and p16, five (7%) tumors were mutated in both genes, with 42% of p16-mutated tumors also containing a p53 mutation (results not shown). G:C Ͼ A:T transitions were the most common mutations observed in the two genes, comprising~33% of both p53 and p16 mutations (Table I) . G:C Ͼ T:A transversions were observed in 22% of p53 and 33% of p16 mutations (total prevalence ϭ 25%; Table I ). This mutational spectrum is similar to that observed in previous studies of oral or head and neck cancer (14, 22) . The median for tobacco use in this cohort of 80 patients was 40.5 pack-years, with the mean age of the ഛ40.5 packyear group 62 Ϯ 14.0 years, as compared to 64.0 Ϯ 9.9 years for subjects who smoked Ͼ40.5 pack-years. A minority of the patients with OCSCC were never-tobacco-users (~16%; n ϭ 13). Figure 1 shows the p53 and p16 mutation prevalence in OCSCCs when patients were stratified in quartiles by tobacco use (i.e. by pack-years). The p53 mutation prevalence was significantly lower in patients from the lowest quartile (i.e. 0-8 pack-years) as compared to patients from the three remaining quartiles (i.e. Ͼ8 pack-years, including one life-long (40-year) never-smoking tobacco chewer; OR ϭ 3.2; CI ϭ 1.0-10.2). This association was also significant (P Ͻ 0.05) when patients were divided into subjects who smoked ഛ30 pack-years (9/34; 26%) as compared to patients who smoked Ͼ30 packyears (23/46; 50%; OR ϭ 2.8; CI ϭ 1.1-7.2; Table II ). The mean (Ϯ SD) pack-years for patients with p53-mutated oral tumors was 51.2 Ϯ 39.1, as compared to 36.6 Ϯ 33.9 packyears for patients with oral tumors exhibiting wild-type p53 (P Ͻ 0.07). Similar to the trend observed by Brennan et al. (22) for never-smokers as compared to smokers, the prevalence of G:C Ͼ A:T transitions was higher (44%) in OCSCCs from subjects who smoked ഛ30 pack-years as compared to tumors from patients who smoked Ͼ30 pack-years (30% ; Table III) . Unlike the pattern observed by Brennan et al. in smokers versus never-smokers (22), a significantly increased prevalence of G:C Ͼ T:A transversions in OCSCCs from patients who smoked Ͼ30 pack-years (26%) as compared to oral tumors from patients who smoked ഛ30 pack-years (11%) was observed in the present study (OR ϭ 2.8, CI ϭ 1.0-31.1; Table III) . This difference between the two studies may, in part, be due to differences in the stratifications used in performing this analysis-no data on p53 mutational spectrum versus packyears of patient tobacco use was provided in Brennan's study. A trend towards an increased prevalence of p16 mutations was also observed in OCSCCs from subjects who smoked Ͼ30 pack-years (OR ϭ 2.3; CI ϭ 0.6-9.4; Table II). A similar non-significant relationship was observed when patients were stratified in approximate quartiles of tobacco use (Figure 1) . However, no significant difference in p16 mutational spectrum (11) 1 (6) 3 (17) a Analysis does not include five patients from whom alcohol data were not obtained. b ND ϭ never drinker; LD ϭ light drinkers; MD ϭ moderate drinkers; HD ϭ heavy drinkers (see Materials and methods for alcohol consumption classification). c Numbers in parentheses denote percentages.
could be observed in OCSCCs when patients were divided by tobacco use at 30 pack-years (Table III) or any other stratification including the median (results not shown). Together, these results suggest that the association between p16 mutation prevalence in OCSCCs and patient tobacco use is weak at best and requires further study of a larger number of oral tumor samples. Sixty-two per cent of the never-smoking patient cohort (n ϭ 8) were never-drinkers (ഛ0.1 shots/day), while 81% (n ϭ 53) of the ever-smokers (i.e. ജ1 pack-year) were ever-drinkers. Similar to results obtained by Brennan et al. (22) , increases in p53 mutation prevalence were observed in tumors from patients who were moderate or heavy drinkers (i.e. Ͼ1 shot/day; 44% combined p53 mutation prevalence) as compared to never-or light drinkers (i.e. ഛ1 shot/day; 33% combined p53 mutation prevalence; Table IV ). However, the average pack-years in tobacco-using never/light drinkers was 40.2 Ϯ 32.8 as compared to 57.2 Ϯ 35.5 pack-years in tobacco-using moderate/heavy drinkers, an increase which approached statistical significance (P Ͻ 0.06). These results suggest that tobacco use was a confounding factor in our analysis of the association of p53 mutation prevalence in oral tumors and alcohol consumption in this series of patients. A similar confounding effect by alcohol consumption on the association between p53 mutation prevalence and patient tobacco use was not observed (results not shown). No correlation between alcohol consumption and p16 mutation prevalence was observed in OCSCCs from this series of patients (Table IV) .
To evaluate the importance of XME genotypes in determining 512 p53 or p16 mutation prevalence in OCSCCs, we examined the distribution of mutations according to GSTM1 null and CYP1A1 ile:val polymorphic genotypes. As shown in Table V , an association between oral tumor p53 mutation prevalence and CYP1A1 [val] genotype (including seven subjects with the ile/val genotype and one subject with the val/val genotype) was observed in patients with OCSCC, although the data did not reach significance (OR ϭ Table V) , and a significant correlation (P Ͻ 0.05) was observed between p53 mutation prevalence and the GSTM1 [ϩ] genotype (including the ϩ/0 and ϩ/ϩ genotypes; OR ϭ 2.7, CI ϭ 1.1-6.8). By contrast, no association was observed between p16 mutation prevalence in OCSCCs with either the GSTM1 null (OR ϭ 0.7, CI ϭ 0.2-2.4) or CYP1A1 (ile:val) (P ϭ 0.10 by Fisher's exact test) genotypes.
Discussion
In the series of oral squamous cell carcinomas examined in this study, the prevalence of p53 mutations (40%) was similar to that described in previous studies for head and neck (22) or oral tumors (13) . p53 mutation induction in OCSCCs (13) or head and neck tumors (22) has been previously linked with increased patient tobacco use. Results from the present study confirm this association, with the p53 mutation prevalence in OCSCCs significantly higher in patients who were heavier smokers. Furthermore, the differential spectrum of G:C Ͼ T:A mutations observed in these tumors when stratifying patients by levels of tobacco use implicates PAHs such as BaP in the induction of these mutations. The increase in p53 mutation prevalence observed in patients who were moderate-heavy drinkers of alcohol is similar to the trend described by Brennan et al. (22) . However, in the latter study, the confounding effects of tobacco use in the alcoholdrinking patient group was not determined (22) . It is welldocumented that alcohol-drinking tobacco users are more likely to be heavier tobacco-users than non-drinking tobacco-users (33) . A near-significant correlation between increased tobacco use with increasing alcohol consumption was indeed demonstrated in the series of patients examined in the present study. Therefore, the increased prevalence of p53 mutations in patients who drank alcohol in both the present and previous studies is likely due to an increased use of tobacco rather than a potentiation of this effect by alcohol itself.
Both CYP1A1 and GSTM1 have been implicated in the metabolism of PAHs like BaP (1, 2) . Differences in the activity or expression of these enzymes have been linked to an increased risk for several tobacco-related cancers (3) (4) (5) (6) . An association between cancer risk and the CYP1A1 ile:val polymorphism at codon 462 of the CYP1A1 gene has been demonstrated for lung (10, 11) and oral cancer (25) . This polymorphism was shown to be linked to an increased prevalence of tobaccoinduced p53 mutations in lung tumors (24) , suggesting a link between mutations in target genes like p53 and carcinogen metabolism pathways in individuals. The role of the GSTM1 (0/0) genotype in risk for tobacco-related cancer induction is more controversial. Although the GSTM1 (0/0) genotype has been correlated with increased risk for lung cancer, this association has not been observed in all studies (5) . Also, the GSTM1 (0/0) genotype was not observed to be correlated with an increased risk for oral cancer (25) . A significant association was not observed between the GSTM1 (0/0) genotype and the prevalence of p53 mutations in lung tumors (24) . To determine if there exists an association between XME genotypes and the induction of mutations in target genes in oral tumors, we examined the prevalence of p53 mutations in oral tumors from patients of known CYP1A1 and GSTM1 genotypes. The prevalence of p53 mutations in oral tumors was higher in patients with the CYP1A1 [val] genotype, and this association was significant in subjects with the combined CYP1A1 [val]/ GSTM1 [ϩ] genotype. These data are consistent with the increased risk for oral cancer described previously for subjects with these genotypes (25) . The CYP1A1 val isozyme exhibits increased activity for the metabolism of several substrates, including 7-ethoxy-resorufin (7-9) and both (R)6-and (R)8-hydroxy-warfarin (9). However, over-expressed valine and isoleucine forms of the CYP1A1 enzyme exhibit similar metabolic activities towards BaP (9) . G:C Ͼ T:A transversions were the most common mutations induced in heavier smokers (Ͼ30 pack-years) and a significant link with CYP1A1 genotype was observed. These data are consistent with the possibility that the different CYP1A1 isoforms may exhibit differential activities towards other PAHs or tobacco carcinogens which induce G:C Ͼ T:A mutations in oral tumors. Such a differentially expressed activity would be consistent with the observed increased risk for both lung (10, 11) and oral (25) cancers in subjects with the CYP1A1 val isoform and with a tobacco carcinogen-induced mechanism of target gene mutation during cancer induction.
The association between p53 mutation prevalence and the GSTM1 [ϩ] genotype is consistent with the increased risk for oral cancer observed in subjects with the combined CYP1A1 [val]/GSTM1 [ϩ] genotype observed previously (25) . Although the mechanism underlying this relationship is presently unclear, it is possible that the presence of the GSTM1 [ϩ] genotype may be linked to other polymorphic genotypes which play a role in p53 mutation induction in oral tumors.
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Alternatively, GSTM1-encoded GST µ protein may somehow be involved in a tobacco carcinogen-metabolizing pathway where the active carcinogen targets p53 for mutation in oral tumors. Further investigations on a larger oral cancer patient cohort will be necessary to more fully evaluate this association.
To determine if any potential associations were target genespecific, we performed a similar analysis for mutations induced in the p16 tumor suppressor gene. The prevalence of p16 base pair substitution or frameshift mutations (16%) in this series of oral tumors was similar to that described for oral carcinomas in previous studies (19, 20) . Ͼ42% of p16-mutated tumors also contained a p53 mutation, suggesting that combined mutations in both tumor suppressor genes may often be necessary for oral tumor induction. A significant trend towards a link between OCSCC p16 mutation induction and patient tobacco use was not observed in this study, and no link between p16 mutational spectrum and patient tobacco use was observed. Furthermore, unlike the pattern observed for p53, the p16 mutation prevalence in this series of oral tumors does not appear to be associated with CYP1A1 or GSTM1 genotype. Therefore, there does not appear to be a strong association between the induction of p16 mutations in OCSCCs and tobacco carcinogenesis. These results suggest that in oral cancer, target-gene mutation specificity is linked to XME genotyping patterns, and that this association is linked to specific carcinogenic mechanisms and metabolic pathways.
In conclusion, the data presented here suggest that independent carcinogenic and metabolic pathways may be involved in the induction of oral cancer. p53 Mutations appear to be preferentially induced upon exposure to tobacco carcinogens, the differential p53 mutational spectrum in tumors from heavy smokers implicates the involvement of PAHs in the induction of these mutations, and the induction of p53 mutations is linked with specific genotypes in PAH-metabolizing enzyme genes (i.e. CYP1A1). Similar associations are not observed for p16 mutations. Together, these data suggest that specific carcinogenic pathways exist in OCSCC tumor induction.
